Sirtuins (SIRTs) As a Novel Target in Gastric Cancer
Abstract
:1. Introduction
2. Gastric Cancer
3. Sirtuins (SIRTs) Family
4. Role of Sirtuins (SIRTs) in Progression and Metastasis of GC Cells
4.1. Sirtuin 1
4.2. Sirtuin 2
4.3. Sirtuin 3
4.4. Sirtuin 4
4.5. Sirtuin 5
4.6. Sirtuin 6
4.7. Sirtuin 7
5. Regulation of SIRTs As a Potential Target in GC Therapy
5.1. Resveratrol
5.2. Dietary Restriction
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Leja, M.; Linē, A. Early detection of gastric cancer beyond endoscopy—new methods. Best Pr. Res. Clin. Gastroenterol. 2021, 101731, 50–51. [Google Scholar] [CrossRef] [PubMed]
- Tay, S.W.; Li, J.W.; Fock, K.M. Diet and cancer of the esophagus and stomach. Curr. Opin. Gastroenterol. 2021, 37, 158–163. [Google Scholar] [CrossRef] [PubMed]
- Loffeld, R.J.; Willems, I.; Flendrig, J.A.; Arends, J.W. Helicobacter pylori and gastric carcinoma. Histopathology 1990, 17, 537–541. [Google Scholar] [CrossRef] [PubMed]
- Vazquez-Torres, A.; Jones-Carson, J.; Balish, E. Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Infect Immun. 1996, 64, 3127–3133. [Google Scholar] [CrossRef] [Green Version]
- Yanaka, A. Sulforaphane enhances protection and repair of gastric mucosa against oxida-tive stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pylori-infected gastric mucosae in mice and human subjects. Curr. Pharm. Des. 2011, 17, 1532–1540. [Google Scholar] [CrossRef]
- Zhou, Y.; Xia, L.; Liu, Q.; Wang, H.; Lin, J.; Oyang, L.; Chen, X.; Luo, X.; Tan, S.; Tian, Y.; et al. Induction of Pro-Inflammatory Response via Activated Macrophage-Mediated NF-κB and STAT3 Pathways in Gastric Cancer Cells. Cell Physiol Biochem. 2018, 47, 1399–1410. [Google Scholar] [CrossRef]
- Quail, D.F.; Joyce, J.A. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013, 19, 1423–1437. [Google Scholar] [CrossRef]
- Barcellos-Hoff, M.H.; Medina, D. New highlights on stroma–epithelial interactions in breast cancer. Breast Cancer Res. 2005, 7, 33–36. [Google Scholar] [CrossRef] [Green Version]
- Haddow, A. Molecular repair, wound healing, and carcinogenesis: Tumor production a possible overhealing? Adv. Cancer Res. 1972, 16, 181–234. [Google Scholar]
- Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl. J. Med. 1986, 315, 1650–1659. [Google Scholar]
- Zeng, D.; Li, M.; Zhou, R.; Zhang, J.; Sun, H.; Shi, M.; Bin, J.; Liao, Y.; Rao, J.; Liao, W. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures. Cancer Immunol. Res. 2019, 7, 737–750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47. [Google Scholar] [CrossRef] [PubMed]
- Morris, B.J. Seven sirtuins for seven deadly diseases of aging. Free Radic. Biol. Med. 2013, 56, 133–171. [Google Scholar] [CrossRef] [PubMed]
- Lavu, S.; Boss, O.; Elliott, P.J.; Lambert, P.D. Sirtuins—novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug. Discov. 2008, 7, 841–853. [Google Scholar] [CrossRef]
- Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450, 712–716. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stein, S.; Matter, C.M. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011, 10, 640–647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, G.; Xia, Z.; Liu, Y.; Meng, F.; Wu, X.; Fang, Y.; Zhang, C.; Liu, D. SIRT1 inhibits rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and inflammatory response via suppressing NF-κB pathway. Biosci. Rep. 2018, 38, BSR20180541. [Google Scholar] [CrossRef] [Green Version]
- Bosch-Presegué, L.; Vaquero, A. The dual role of sirtuins in cancer. Genes Cancer 2011, 2, 648–662. [Google Scholar] [CrossRef]
- Palmirotta, R.; Cives, M.; Della-Morte, D.; Capuani, B.; Lauro, D.; Guadagni, F.; Silvestris, F. Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. Oxid. Med. Cell Longev. 2016, 2016, 3031459. [Google Scholar] [CrossRef] [Green Version]
- Thrumurthy, S.G.; Chaudry, M.A.; Hochhauser, D.; Mughal, M. The diagnosis and management of gastric cancer. BMJ 2013, 347, f6367. [Google Scholar] [CrossRef] [Green Version]
- Hallinan, J.T.; Venkatesh, S.K. Gastric carcinoma: Imaging diagnosis, staging and assessment of treatment response. Cancer Imaging 2013, 13, 12–27. [Google Scholar] [CrossRef] [Green Version]
- Johnston, F.M.; Beckman, M. Updates on Management of Gastric Cancer. Curr. Oncol. Rep. 2019, 21, 7. [Google Scholar] [CrossRef]
- Tkacz, M.; Tarnowski, M.; Staniszewska, M.; Pawlik, A. Role of prometastatic factors in gastric cancer development. Postep. Hig. Med. Dosw. Online 2016, 70, 1367–1377. [Google Scholar]
- Nguyen, D.K.; Maggard-Gibbons, M. Age, poverty, acculturation, and gastric cancer. Surgery 2013, 154, 444–452. [Google Scholar] [CrossRef]
- Farrow, D.C.; Vaughan, T.L.; Sweeney, C.; Gammon, M.D.; Chow, W.H.; Risch, H.A.; Stanford, J.L.; Hansten, P.D.; Mayne, S.T.; Schoenberg, J.B.; et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control. 2000, 11, 231–238. [Google Scholar] [CrossRef]
- Maddineni, G.; Xie, J.J.; Brahmbhatt, B.; Mutha, P. Diet and carcinogenesis of gastric cancer. Curr. Opin. Gastroenterol. 2022, 38, 588–591. [Google Scholar] [CrossRef]
- Pazdur, R.; Wagman, L.D.; Camphausen, K.A.; Hoskins, W.J. Nowotwory złośliwe. Postępowanie wielodyscyplinarne. Leczenie systemowe, chirurgia, radioterapia. Czelej 2012, 1, 189–198. [Google Scholar]
- Song, Z.; Wu, Y.; Yang, J.; Yang, D.; Fang, X. Progress in the treatment of advanced gastric cancer. Tumour. Biol. 2017, 39, 1010428317714626. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giampieri, R.; Del Prete, M.; Cantini, L.; Baleani, M.G.; Bittoni, A.; Maccaroni, E.; Berardi, R. Optimal management of resected gastric cancer. Cancer Manag. Res. 2018, 10, 1605–1618. [Google Scholar] [CrossRef] [Green Version]
- Tang, X.; Li, G.; Su, F.; Cai, Y.; Shi, L.; Meng, Y.; Liu, Z.; Sun, J.; Wang, M.; Qian, M.; et al. HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration. Nucleic Acids Res. 2020, 48, 2912–2923. [Google Scholar] [CrossRef] [PubMed]
- Verdin, E.; Hirschey, M.D.; Finley, L.W.; Haigis, M.C. Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling. Trends Biochem. Sci. 2010, 35, 669–675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.; Wang, L.; Meng, L.; Cao, G.; Wu, Y. Sirtuin 6 overexpression relieves sepsis-induced acute kidney injury by promoting autophagy. Cell Cycle 2019, 18, 425–436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kiran, S.; Anwar, T.; Kiran, M.; Ramakrishna, G. Sirtuin 7 in cell proliferation, stress and disease: Rise of the Seventh Sirtuin! Cell Signal 2015, 27, 673–682. [Google Scholar] [CrossRef] [PubMed]
- Duan, J.L.; Ruan, B.; Song, P.; Fang, Z.Q.; Yue, Z.S.; Liu, J.J.; Dou, G.R.; Han, H.; Wang, L. Shear stress-induced cellular senescence blunts liver regeneration through Notch-sirtuin 1-P21/P16 axis. Hepatology 2022, 75, 584–599. [Google Scholar] [CrossRef] [PubMed]
- Calabrese, V.; Cornelius, C.; Leso, V.; Trovato-Salinaro, A.; Ventimiglia, B.; Cavallaro, M.; Scuto, M.; Rizz, A.S.; Zanoli, L.; Neri, S.; et al. Oxidative stress, glutathione status, sirtuin and cellular stress response in type 2 diabetes. Biochim. Biophys. Acta 2012, 1822, 729–736. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Korotkov, A.; Seluanov, A.; Gorbunova, V. Sirtuin 6: Linking longevity with genome and epigenome stability. Trends Cell Biol. 2021, 31, 994–1006. [Google Scholar] [CrossRef] [PubMed]
- Weichert, W.; Roske, A.; Niesporek, S.; Noske, A.; Buckendahl, A.C.; Dietel, M.; Gekeler, V.; Boehm, M.; Beckers, T.; Denkert, C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo. Clin. Cancer Res. 2008, 14, 1669–1677. [Google Scholar] [CrossRef] [Green Version]
- Yamamoto, H.; Schoonjans, K.; Auwerx, J. Sirtuin Functions in Health and Disease. Mol. Endocrinol. 2007, 21, 1745–1755. [Google Scholar] [CrossRef] [Green Version]
- Khawar, M.B.; Liu, C.; Gao, F.; Gao, H.; Liu, W.; Han, T.; Wang, L.; Li, G.; Jiang, H.; Li, W. Sirt1 regulates testosterone biosynthesis in Leydig cells via modulating autophagy. Protein Cell 2021, 12, 67–75. [Google Scholar] [CrossRef]
- Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.; Puigserver, P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434, 113–118. [Google Scholar] [CrossRef] [PubMed]
- Mouchiroud, L.; Houtkooper, R.H.; Moullan, N.; Katsyuba, E.; Ryu, D.; Cantó, C.; Mottis, A.; Jo, Y.S.; Viswanathan, M.; Schoonjans, K.; et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell 2013, 154, 430–441. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akter, R.; Afrose, A.; Rahman, M.R.; Chowdhury, R.; Nirzhor, S.S.R.; Khan, R.I.; Kabir, M.T. A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer’s Disease, Aging, Cancer, Inflammation, and Diabetes. Int. J. Mol. Sci. 2021, 22, 4180. [Google Scholar] [CrossRef]
- Zhao, Q.; Zhou, J.; Li, F.; Guo, S.; Zhang, L.; Li, J.; Qi, Q.; Shi, Y. The Role and Therapeutic Perspectives of Sirtuin 3 in Cancer Metabolism Reprogramming, Metastasis, and Chemoresistance. Front Oncol. 2022, 12, 910963. [Google Scholar] [CrossRef]
- Steriade, C.; Titulaer, M.J.; Vezzani, A.; Sander, J.W.; Thijs, R.D. The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain 2021, 144, 372–390. [Google Scholar] [CrossRef] [PubMed]
- Dupuy, F.; Tabariès, S.; Andrzejewski, S.; Dong, Z.; Blagih, J.; Annis, M.G.; Omeroglu, A.; Gao, D.; Leung, S.; Amir, E.; et al. PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metab. 2015, 22, 577–589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gyamfi, J.; Kim, J.; Choi, J. Cancer as a Metabolic Disorder. Int. J. Mol. Sci. 2022, 23, 1155. [Google Scholar] [CrossRef]
- Rasha, F.; Mims, B.M.; Castro-Piedras, I.; Barnes, B.J.; Grisham, M.B.; Rahman, R.L.; Pruitt, K. The Versatility of Sirtuin-1 in Endocrinology and Immunology. Front Cell Dev. Biol. 2020, 8, 1370. [Google Scholar] [CrossRef] [PubMed]
- Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23, 2369–2380. [Google Scholar] [CrossRef] [Green Version]
- Schug, T.T.; Xu, Q.; Gao, H.; Peres-Da-Silva, A.; Draper, D.W.; Fessler, M.; Purushotham, A.; Li, X. Myeloid Deletion of SIRT1 Induces Inflammatory Signaling in Response to Environmental Stress. Mol. Cell. Biol. 2010, 30, 4712–4721. [Google Scholar] [CrossRef] [Green Version]
- Legutko, A.; Marichal, T.; Fievez, L.; Bedoret, D.; Mayer, A.; De Vries, H.; Klotz, L.; Drion, P.V.; Heirman, C.; Cataldo, D.; et al. Sirtuin 1 Promotes Th2 Responses and Airway Allergy by Repressing Peroxisome Proliferator-Activated Receptor-γ Activity in Dendritic Cells. J. Immunol. 2011, 187, 4517–4529. [Google Scholar] [CrossRef] [Green Version]
- Zhao, E.; Hou, J.; Ke, X.; Abbas, M.N.; Kausar, S.; Zhang, L.; Cui, H. The Roles of Sirtuin Family Proteins in Cancer Progression. Cancers 2019, 11, 1949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, R.H.; Zheng, Y.; Kim, H.S.; Xu, X.; Cao, L.; Luhasen, T.; Lee, M.H.; Xiao, C.; Vassilopoulos, A.; Chen, W. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 2008, 32, 11–20. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Y.; Sun, X.; Ji, K.; Du, L.; Xu, C.; He, N.; Wang, J.; Liu, Y.; Liu, Q. Sirt3-mediated mitochondrial fission regulates the colorectal cancer stress response by modulating the Akt/PTEN signalling pathway. Biomed. Pharm. 2018, 105, 1172–1182. [Google Scholar] [CrossRef] [PubMed]
- Nakahara, Y.; Yamasaki, M.; Sawada, G.; Miyazaki, Y.; Makino, T.; Takahashi, T.; Kurokawa, Y.; Nakajima, K.; Takiguchi, S.; Mimori, K. Downregulation of SIRT4 Expression Is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma. Oncology 2016, 90, 347–355. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.S.; Du, L.; Liang, X.; Meng, P.; Bi, L.; Wang, Y.L.; Wang, C.; Tang, B. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. Hepatology 2019, 69, 1614–1631. [Google Scholar] [CrossRef] [PubMed]
- Dong, X.C.; Jing, L.M.; Wang, W.X.; Gao, Y.X. Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. Biochem. Biophys. Res. Commun. 2016, 475, 245–250. [Google Scholar] [CrossRef]
- Huang, S.; Guo, H.; Cao, Y.; Xiong, J. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. Pathol. Res. Pract. 2019, 215, 794–800. [Google Scholar] [CrossRef]
- Hoffmann, G.; Breitenbucher, F.; Schuler, M.; Ehrenhofer-Murray, A.E. A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. J. Biol. Chem. 2014, 289, 5208–5216. [Google Scholar] [CrossRef] [Green Version]
- Sasca, D.; Hahnel, P.S.; Szybinski, J.; Khawaja, K.; Kriege, O.; Pante, S.V.; Bullinger, L.; Strand, S.; Strand, D.; Theobald, M. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia. Blood 2014, 124, 121–133. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Quan, Y.; Wang, N.; Chen, Q.; Xu, J.; Cheng, W.; Di, M.; Xia, W.; Gao, W.Q. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. Oncotarget 2015, 6, 26494–26507. [Google Scholar] [CrossRef] [Green Version]
- Wu, Z.P.; Fang, H.X. Expression of SIRT5 protein in gastric cancer cells. J Biol Regul Homeost Agents. 2019, 33, 1675–1683. [Google Scholar]
- Li, Y.; Zhang, M.; Dorfman, R.G.; Pan, Y.; Tang, D.; Xu, L.; Zhao, Z.; Zhou, Q.; Zhou, L.; Wang, Y.; et al. SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism. Neoplasia 2018, 20, 745–756. [Google Scholar] [CrossRef]
- Zhang, S.; Chen, P.; Huang, Z.; Hu, X.; Chen, M.; Hu, S.; Hu, Y.; Cai, T. Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a. Sci. Rep. 2015, 5, 9787. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dong, G.; Wang, B.; An, Y.; Li, J.; Wang, X.; Jia, J.; Yang, Q. SIRT1 suppresses the migration and invasion of gastric cancer by regulating ARHGAP5 expression. Cell Death Dis. 2018, 9, 977. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sun, H.; Huang, D.; Liu, G.; Jian, F.; Zhu, J.; Zhang, L. SIRT4 acts as a tumor suppressor in gastric cancer by inhibiting cell proliferation, migration, and invasion. Onco. Targets Ther. 2018, 11, 3959–3968. [Google Scholar] [CrossRef]
- Zandi, S.; Hedayati, M.A.; Mohammadi, E.; Sheikhesmaeili, F. Helicobacter pylori infection increases sirt2 gene expression in gastric epithelial cells of gastritis patients. Microb. Pathog. 2018, 116, 120–123. [Google Scholar] [CrossRef] [PubMed]
- Mohammadi Saravle, S.; Ahmadi Hedayati, M.; Mohammadi, E.; Sheikhesmaeili, F.; Nikkhou, B. Sirt1 Gene Expression and Gastric Epithelial Cells Tumor Stage in Patients with Helicobacter pylori Infection. Asian Pac. J. Cancer Prev. 2018, 19, 913–916. [Google Scholar]
- Zhu, H.; Xia, L.; Zhang, Y.; Wang, H.; Xu, W.; Hu, H.; Wang, J.; Xin, J.; Gang, Y.; Sha, S.; et al. Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS ONE 2012, 7, e31431. [Google Scholar] [CrossRef] [Green Version]
- Yang, Q.; Wang, B.; Zang, W.; Wang, X.; Liu, Z.; Li, W.; Jia, J. Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS ONE 2013, 8, e70627. [Google Scholar] [CrossRef]
- Wang, H.; Feng, K.; Wang, Q.; Deng, H. Reciprocal interaction between SIRT6 and APC/C regulates genomic stability. Sci. Rep. 2021, 11, 14253. [Google Scholar] [CrossRef]
- Roth, M.; Chen, W.Y. Sorting out functions of sirtuins in cancer. Oncogene 2014, 33, 1609–1620. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brooks, C.L.; Gu, W. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 2009, 9, 123–128. [Google Scholar] [CrossRef]
- Song, N.Y.; Surh, Y.J. Janus-faced role of SIRT1 in tumorigenesis. Ann. NY Acad Sci. 2012, 1271, 10–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, H.; Liu, N.; Zhao, Y.; Zhu, X.; Wang, C.; Liu, Q.; Gao, C.; Zhao, X.; Li, J. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. Aging 2019, 11, 9643–9660. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Huang, S.; Deng, C.; Cao, Y.; Yang, J.; Chen, G.; Zhang, B.; Duan, C.; Shi, J.; Kong, B.; et al. Co-ordinated overexpression of SIRT1 and STAT3 is associated with poor survival outcome in gastric cancer patients. Oncotarget 2017, 8, 18848–18860. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.Y.; Ko, Y.S.; Park, J.; Choi, Y.; Park, J.W.; Kim, Y.; Pyo, J.S.; Yoo, Y.B.; Lee, J.S.; Lee, B.L. Forkhead Transcription Factor FOXO1 Inhibits Angiogenesis in Gastric Cancer in Relation to SIRT1. Cancer Res Treat. 2016, 48, 345–354. [Google Scholar] [CrossRef] [PubMed]
- Cha, E.J.; Noh, S.J.; Kwon, K.S.; Kim, C.Y.; Park, B.H.; Park, H.S.; Lee, H.; Chung, M.J.; Kang, M.J.; Lee, D.G.; et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 2009, 15, 4453–4459. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, L.; Wang, W.Y.; Cao, L.P. SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. Int. J. Clin. Exp. Med. 2015, 8, 5263–5271. [Google Scholar]
- Lee, D.Y.; Jung, D.E.; Yu, S.S.; Lee, Y.S.; Choi, B.K.; Lee, Y.C. Regulation of SIRT3 signal related metabolic reprogramming in gastric cancer by Helicobacter pylori oncoprotein CagA. Oncotarget 2017, 8, 78365–78378. [Google Scholar] [CrossRef] [Green Version]
- Yang, B.; Fu, X.; Shao, L.; Ding, Y.; Zeng, D. Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer. Biochem. Biophys. Res. Commun. 2014, 443, 156–160. [Google Scholar] [CrossRef]
- Lee, H.; Yuh, Y.; Kim, S. Serum lactate dehydrogenase (LDH) level as a prognostic factor for the patients with advanced gastric cancer. Journal of Clinical Oncology 2009, 27, 15. [Google Scholar] [CrossRef]
- Hu, Y.; Lin, J.; Lin, Y.; Chen, X.; Zhu, G.; Huang, G. Overexpression of SIRT4 inhibits the proliferation of gastric cancer cells through cell cycle arrest. Oncol. Lett. 2019, 17, 2171–2176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, Z.; Li, L.; Tang, Y.; Xie, D.; Wu, K.; Wei, W.; Xiao, Q. CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer. Cancer Sci. 2018, 109, 2590–2598. [Google Scholar] [CrossRef] [Green Version]
- Zhou, J.; Wu, A.; Yu, X.; Zhu, J.; Dai, H. SIRT6 inhibits growth of gastric cancer by inhibiting JAK2/STAT3 pathway. Oncol. Rep. 2017, 38, 1059–1066. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tanno, M.; Sakamoto, J.; Miura, T.; Shimamoto, K.; Horio, Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J. Biol. Chem. 2007, 282, 6823–6832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, M.; Wei, W.; Xiao, X.; Guo, J.; Xie, X.; Li, L.; Kong, Y.; Lv, N.; Jia, W.; Zhang, Y.; et al. Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med. Oncol. 2012, 29, 3240–3249. [Google Scholar] [CrossRef] [PubMed]
- Lv, L.; Shen, Z.; Zhang, J.; Zhang, H.; Dong, J.; Yan, Y.; Liu, F.; Jiang, K.; Ye, Y.; Wang, S. Clinicopathological significance of SIRT1 expression in colorectal adenocarcinoma. Med. Oncol. 2014, 31, 965. [Google Scholar] [CrossRef]
- Choi, H.N.; Bae, J.S.; Jamiyandorj, U.; Noh, S.J.; Park, H.S.; Jang, K.Y.; Chung, M.J.; Kang, M.J.; Lee, D.G.; Moon, W.S. Expression and role of SIRT1 in hepatocellular carcinoma. Oncol. Rep. 2011, 26, 503–510. [Google Scholar]
- Kim, J.R.; Moon, Y.J.; Kwon, K.S.; Bae, J.S.; Wagle, S.; Yu, T.K.; Kim, K.M.; Park, H.S.; Lee, J.H.; Moon, W.S.; et al. Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS ONE 2013, 8, e74738. [Google Scholar] [CrossRef] [Green Version]
- Huffman, D.M.; Grizzle, W.E.; Bamman, M.M.; Kim, J.S.; Eltoum, I.A.; Elgavish, A.; Nagy, T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007, 67, 6612–6618. [Google Scholar] [CrossRef] [Green Version]
- Jang, K.Y.; Kim, K.S.; Hwang, S.H.; Kwon, K.S.; Kim, K.R.; Park, H.S.; Park, B.H.; Chung, M.J.; Kang, M.J.; Lee, D.G.; et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 2009, 41, 366–371. [Google Scholar] [CrossRef]
- Jang, K.Y.; Hwang, S.H.; Kwon, K.S.; Kim, K.R.; Choi, H.N.; Lee, N.R.; Kwak, J.Y.; Park, B.H.; Park, H.S.; Chung, M.J.; et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2008, 32, 1523–1531. [Google Scholar] [CrossRef]
- Feng, A.N.; Zhang, L.H.; Fan, X.S.; Huang, Q.; Ye, Q.; Wu, H.Y.; Yang, J. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int. J. Surg. Pathol. 2011, 19, 743–750. [Google Scholar] [CrossRef]
- Kabra, N.; Li, Z.; Chen, L.; Li, B.; Zhang, X.; Wang, C.; Yeatman, T.; Coppola, D.; Chen, J. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem. 2009, 284, 18210–18217. [Google Scholar] [CrossRef] [Green Version]
- Jang, S.H.; Min, K.W.; Paik, S.S.; Jang, K.S. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J. Clin. Pathol. 2012, 65, 735–739. [Google Scholar] [CrossRef]
- Yang, Q.; Wang, B.; Gao, W.; Huang, S.; Liu, Z.; Li, W.; Jia, J. SIRT1 is downregulated in gastric cancer and leads to G1-phase arrest via NF-κB/Cyclin D1 signaling. Mol. Cancer Res. 2013, 11, 1497–1507. [Google Scholar] [CrossRef] [Green Version]
- Qiu, G.; Li, X.; Che, X.; Wei, C.; He, S.; Lu, J.; Jia, Z.; Pang, K.; Fan, L. SIRT1 is a regulator of autophagy: Implications in gastric cancer progression and treatment. FEBS Lett. 2015, 589, 2034–2042. [Google Scholar] [CrossRef] [Green Version]
- Yan, H.; Qiu, C.; Sun, W.; Gu, M.; Xiao, F.; Zou, J.; Zhang, L. Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy. Oncol. Rep. 2018, 39, 1671–1681. [Google Scholar] [CrossRef]
- Lu, J.; Zhang, L.; Chen, X.; Lu, Q.; Yang, Y.; Liu, J.; Ma, X. SIRT1 counteracted the activation of STAT3 and NF-κB to repress the gastric cancer growth. Int. J. Clin. Exp. Med. 2014, 7, 5050–5058. [Google Scholar]
- Papierska, K.; Krajka-Kuźniak, V. STAT3 as a therapeutic target. Farm. Współczesna 2020, 13, 29–34. [Google Scholar]
- Kang, Y.; Jung, W.Y.; Lee, H.; Lee, E.; Kim, A.; Kim, B.H. Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma. Korean J. Pathol. 2012, 46, 523–531. [Google Scholar] [CrossRef] [PubMed]
- Li, H.; Che, X.M.; Zhao, W.; He, S.C.; Zhang, Z.L.; Chen, R.; Fan, L.; Jia, Z.L. Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop. Oncol. Rep. 2013, 30, 2153–2160. [Google Scholar] [CrossRef] [Green Version]
- Huang, K.H.; Hsu, C.C.; Fang, W.L.; Chi, C.W.; Sung, M.T.; Kao, H.L.; Li, A.F.; Yin, P.H.; Yang, M.H.; Lee, H.C. SIRT3 expression as a biomarker for better prognosis in gastric cancer. World J. Surg. 2014, 38, 910–917. [Google Scholar] [CrossRef]
- Mahjabeen, I.; Rizwan, M.; Fareen, G.; Waqar Ahmed, M.; Farooq Khan, A.; Akhtar Kayani, M. Mitochondrial sirtuins genetic variations and gastric cancer risk: Evidence from retrospective observational study. Gene 2021, 807, 145951. [Google Scholar] [CrossRef]
- Costa-Machado, L.F.; Fernandez-Marcos, P.J. The sirtuin family in cancer. Cell Cycle 2019, 18, 2164–2196. [Google Scholar] [CrossRef] [PubMed]
- Huang, G.; Cui, F.; Yu, F.; Lu, H.; Zhang, M.; Tang, H.; Peng, Z. Sirtuin-4 (SIRT4) is downregulated and associated with some clinicopathological features in gastric adenocarcinoma. Biomed Pharm. 2015, 72, 135–139. [Google Scholar] [CrossRef] [PubMed]
- Wang, F.; Wang, K.; Xu, W.; Zhao, S.; Ye, D.; Wang, Y.; Xu, Y.; Zhou, L.; Chu, Y.; Zhang, C.; et al. SIRT5 desuccinylates and activates pyruvate kinase M2 to block macrophage IL-1β production and to prevent DSS-induced colitis in mice. Cell Rep. 2017, 19, 2331–2344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yang, X.; Liu, B.; Zhu, W.; Luo, J. SIRT5, functions in cellular metabolism with a multiple enzymatic activities. Sci. China Life Sci. 2015, 58, 912–914. [Google Scholar] [CrossRef] [Green Version]
- Gu, W.; Qian, Q.; Xu, Y.; Xu, X.; Zhang, L.; He, S.; Li, D. SIRT5 regulates autophagy and apoptosis in gastric cancer cells. J. Int. Med. Res. 2021, 49, 1–15. [Google Scholar] [CrossRef]
- Mostoslavsky, R.; Chua, K.F.; Lombard, D.B.; Pang, W.W.; Fischer, M.R.; Gellon, L.; Liu, P.; Mostoslavsky, G.; Franco, S.; Murphy, M.M.; et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124, 315–329. [Google Scholar] [CrossRef]
- Desantis, V.; Lamanuzzi, A.; Vacca, A. The role of SIRT6 in tumors. Hematologica 2008, 103, 1–4. [Google Scholar] [CrossRef] [Green Version]
- Satoh, K. Sirtuin-7 as a Novel Therapeutic Target in Vascular Smooth Muscle Cell Proliferation and Remodeling. Circ. J. 2021, 85, 2241–2242. [Google Scholar] [CrossRef]
- Lee, H.S.; Jung, W.; Lee, E.; Chang, H.; Choi, J.H.; Kim, H.G.; Kim, A.; Kim, B.H. SIRT7, H3K18ac, and ELK4 Immunohistochemical Expression in Hepatocellular Carcinoma. J. Pathol. Transl. Med. 2016, 50, 337–344. [Google Scholar] [CrossRef] [Green Version]
- Yang, G.; Chang, C.C.; Yang, Y.; Yuan, L.; Xu, L.; Ho, C.T.; Li, S. Resveratrol Alleviates Rheumatoid Arthritis via Reducing ROS and Inflammation, Inhibiting MAPK Signaling Pathways, and Suppressing Angiogenesis. J. Agric. Food Chem. 2018, 66, 12953–12960. [Google Scholar] [CrossRef]
- Lin, Z.; Fang, D. The Roles of SIRT1 in Cancer. Genes Cancer 2013, 4, 97–104. [Google Scholar] [CrossRef] [Green Version]
- Mahady, G.B.; Pendland, S.L. Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am. J. Gastroenterol. 2000, 95, 1849. [Google Scholar] [CrossRef]
- Zhang, X.; Jiang, A.; Qi, B.; Ma, Z.; Xiong, Y.; Dou, J.; Wang, J. Resveratrol Protects against Helicobacter pylori-Associated Gastritis by Combating Oxidative Stress. Int. J. Mol. Sci. 2015, 16, 27757–27769. [Google Scholar] [CrossRef] [Green Version]
- Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218–220. [Google Scholar] [CrossRef] [Green Version]
- Damianaki, A.; Bakogeorgou, E.; Kampa, M.; Notas, G.; Hatzoglou, A.; Panagiotou, S.; Gemetzi, C.; Kouroumalis, E.; Martin, P.M.; Castanas, E. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J. Cell Biochem. 2000, 78, 429–441. [Google Scholar] [CrossRef]
- Ding, X.Z.; Adrian, T.E. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 2002, 25, e71–e76. [Google Scholar] [CrossRef]
- Hsieh, T.C.; Wu, J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 1999, 249, 109–115. [Google Scholar] [CrossRef] [PubMed]
- Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr. 2001, 131, 2197–2203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Catalgol, B.; Batirel, S.; Taga, Y.; Ozer, N.K. Resveratrol: French paradox revisited. Front. Pharm. 2012, 3, 141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zulueta, A.; Caretti, A.; Signorelli, P.; Ghidoni, R. Resveratrol: A potential challenger against gastric cancer. World J. Gastroenterol. 2015, 21, 10636–10643. [Google Scholar] [CrossRef]
- Wang, Z.; Li, W.; Meng, X.; Jia, B. Resveratrol induces gastric cancer cell apoptosis via reactive oxygen species, but independent of sirtuin1. Clin. Exp. Pharmacol. Physiol. 2012, 39, 227–232. [Google Scholar] [CrossRef]
- Buhrmann, C.; Shayan, P.; Popper, B.; Goel, A.; Shakibaei, M. Sirt1 Is Required for Resvera-trol-Mediated Chemopreventive Effects in Colorectal Cancer Cells. Nutrients 2016, 8, 145. [Google Scholar] [CrossRef] [Green Version]
- Buhrmann, C.; Shayan, P.; Goel, A.; Shakibaei, M. Resveratrol Regulates Colorectal Cancer Cell Invasion by Modulation of Focal Adhesion Molecules. Nutrients 2017, 9, 1073. [Google Scholar] [CrossRef] [Green Version]
- Buhrmann, C.; Shayan, P.; Brockmueller, A.; Shakibaei, M. Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Mi-croenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment Study. Molecules 2020, 25, 4292. [Google Scholar] [CrossRef]
- Albanes, D. Caloric intake, body weight, and cancer: A review. Nutr. Cancer 1987, 9, 199–217. [Google Scholar] [CrossRef]
- Kim, S.Y.; Kwak, J.H.; Eun, C.S.; Han, D.S.; Kim, Y.S.; Song, K.S.; Choi, B.Y.; Kim, H.J. Gastric Cancer Risk Was Associated with Dietary Factors Irritating the Stomach Wall: A Case-Control Study in Korea. Nutrients 2022, 14, 2233. [Google Scholar] [CrossRef]
- Kim, J.; Oh, A.; Truong, H.; Laszkowska, M.; Camargo, M.C.; Abrams, J.; Hur, C. Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model. Cancer Med. 2021, 10, 684–692. [Google Scholar] [CrossRef] [PubMed]
- Shah, S.K.; Sunuwar, D.R.; Chaudhary, N.K.; Rai, P.; Pradhan, P.M.S.; Subedi, N.; Devkota, M.D. Dietary Risk Factors Associated with Development of Gastric Cancer in Nepal: A Hospital-Based Case-Control Study. Gastroenterol. Res. Pract. 2020, 2020, 5202946. [Google Scholar] [CrossRef] [PubMed]
- Inoue, K.; Yoshiuchi, S.; Yoshida, M.; Nakamura, N.; Nakajima, S.; Kitamura, A.; Mouri, K.; Michiura, T.; Mukaide, H.; Ozaki, T.; et al. Preoperative weight loss program involving a 20-day very low-calorie diet for obesity before laparoscopic gastrectomy for gastric cancer. Asian J. Endosc. Surg. 2019, 12, 43–50. [Google Scholar] [CrossRef] [Green Version]
- Li, J.H.; Han, L.; Du, T.P.; Guo, M.J. The effect of low-nitrogen and low-calorie parenteral nutrition combined with enteral nutrition on inflammatory cytokines and immune functions in patients with gastric cancer: A double blind placebo trial. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 1345–1350. [Google Scholar] [PubMed]
- Otto, C.; Kaemmerer, U.; Illert, B.; Muehling, B.; Pfetzer, N.; Wittig, R.; Voelker, H.U.; Thiede, A.; Coy, J.F. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008, 8, 122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, B.; Li, X.; Zhou, L.; Wang, Y.; Shang, P. SIRT1: A potential tumour biomarker and therapeutic target. J. Drug. Target. 2019, 27, 1046–1052. [Google Scholar] [CrossRef]
Name | Function | References |
---|---|---|
SIRT1 | inhibits GC cell proliferation and tumor growth; GC growth and metastasis by FOXO1 and YAP signaling; participates in mitophagy; deacetylation of histone substrates, transcription factors and cofactors (p53, STAT3, DBC1, FOXO, c-Myc & Ku70); RSV prevents STAT3 and NF-κB activation; | [64,67,74,75,76,77] |
SIRT2 | influences the migration and invasion of GC cells to metastatic niche; | [62] |
SIRT3 | inhibition of NOTCH1 expression; blocking SIRT3 expression promoted cell division and tumor growth; decreased HIF-1α and ROS production; promoting proliferation, glucose uptake, MnSOD activity; | [78,79,80,81] |
SIRT4 | inhibiting cell proliferation, migration, and invasion; reduces the number of colonies formed by GC cells; stops the cell cycle in the G1 phase; | [65,82] |
SIRT5 | promotes autophagy; reduces the number of colonies and the viability of GC cells; | [83] |
SIRT6 | inhibits cell viability, proliferation, colony formation, and cell cycle; increases apoptosis; inhibits the JAK2/STAT3 pathway; | [84] |
SIRT7 | promotes GC cells proliferation and growth; cell survival and migration; inhibits apoptosis; | [30,63] |
Name | Modulated By |
---|---|
SIRT1 | natural: resveratrol, quercetin, apigenin, catechin, epicatechin, theobromine, curcumin, soy isoflavones, sulforaphane, olivetol, isothiocyanates, piceatannol, cinnamon; |
synthetic: S17834, SRT1720; | |
SIRT2 | synthetic: tempol, (SOD1), 1,4-DHP derivative; |
SIRT3 | natural: resveratrol, epicatechin, curcumin, piceatannol; |
synthetic: acetyl-CPS1,1,4-DHP derivative; | |
SIRT4 | natural: resveratrol, curcumin; |
synthetic: DMS-CPS, HMG-CPS1, acetyl-CPS1; | |
SIRT5 | snatural: piceatannol; |
synthetic: succinyl peptide, DMS-CPS, HMG-CPS1, UBCS039; | |
SIRT6 | natural: iso-quercetin, luteolin, and cyanidin; |
synthetic: tempol, copper-zinc superoxide dismutase (SOD1) mimetic, pyrrole (1,2a) quinoxaline derivative, UBCS039; |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Poniewierska-Baran, A.; Warias, P.; Zgutka, K. Sirtuins (SIRTs) As a Novel Target in Gastric Cancer. Int. J. Mol. Sci. 2022, 23, 15119. https://doi.org/10.3390/ijms232315119
Poniewierska-Baran A, Warias P, Zgutka K. Sirtuins (SIRTs) As a Novel Target in Gastric Cancer. International Journal of Molecular Sciences. 2022; 23(23):15119. https://doi.org/10.3390/ijms232315119
Chicago/Turabian StylePoniewierska-Baran, Agata, Paulina Warias, and Katarzyna Zgutka. 2022. "Sirtuins (SIRTs) As a Novel Target in Gastric Cancer" International Journal of Molecular Sciences 23, no. 23: 15119. https://doi.org/10.3390/ijms232315119